Implanted Electrical Stimulator for the Spinal Cord (for New Jersey Only)
Medical policy governing use and coverage of implanted spinal cord stimulators (SCS) and dorsal root ganglion (DRG) stimulators for members in New Jersey; describes covered and not‑covered indications, coding references, and documentation expectations.
Revised list of proven and medically necessary conditions; replaced 'painful lower limb diabetic neuropathy' with 'painful diabetic neuropathy'.
Replaced language limiting DRG stimulation to FDA-labeled indications by removing the word 'when' to clarify the statement.
Added explicit requirements about medical records documentation that may be required to assess whether the member meets clinical criteria for coverage and what that documentation should include.
Updated Clinical Evidence and References sections to reflect the most current information.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.